Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...

Novo Nordisk's involve the GLP-1 pathway ... which was evident at the recent ObesityWeek 2024, an annual meeting highlighting ...

The Department of Health & Family Welfare, Nagaland held a consultative meeting with members of Novo Nordisk Foundation (NNF) ...